ETHNOPHARMACOLOGICAL RELEVANCE: Asiasari radix is prepared from Asiasarum sieboldii F. Maekawa or Asiasarum heterotropoides F. Maekawa var. mandshuricum F. Maekawa, widely used for treatment of various tussive, inflammatory, allergic diseases and pain. AIM OF STUDY: The antinociceptive effects of Asiasari radix extract (ARE) in mice were examined. MATERIALS AND METHODS: Tail-flick, tail-pressure, hot-plate and formalin tests were used to evaluate its antinociceptive activity. Moreover, N-methyl-D-aspartic acid (NMDA)-induced nociceptive response was also examined. RESULTS: Oral administration of ARE did not affect the responses of the tail-flick, tail-pressure, or hot-plate test or the first phase of the formalin tests, but it dose-dependently decreased the duration of nociceptive behavior in the second phase, as did diclofenac, a non-steroidal anti-inflammatory drug. ARE also inhibited nociceptive behaviors induced by the intrathecal injection of NMDA, although diclofenac did not affect these behaviors. Pretreatment with bicuculline, a GABA(A) antagonist, reduced the antinociceptive effects of ARE on the formalin- or NMDA-induced behaviors. Muscimol, a GABA(A) agonist, exhibited antinociceptive effects in the formalin test and NMDA-induced behaviors in a manner similar to that of ARE. On the other hand, diclofenac significantly inhibited cyclooxygenase (COX)-1 and -2 activities, while ARE did not. CONCLUSION: These results suggest that ARE may inhibit development of hyperalgesia via NMDA receptors based on activation of GABA(A) receptors in the spinal cord.
ETHNOPHARMACOLOGICAL RELEVANCE: Asiasari radix is prepared from Asiasarum sieboldii F. Maekawa or Asiasarum heterotropoides F. Maekawa var. mandshuricum F. Maekawa, widely used for treatment of various tussive, inflammatory, allergic diseases and pain. AIM OF STUDY: The antinociceptive effects of Asiasari radix extract (ARE) in mice were examined. MATERIALS AND METHODS: Tail-flick, tail-pressure, hot-plate and formalin tests were used to evaluate its antinociceptive activity. Moreover, N-methyl-D-aspartic acid (NMDA)-induced nociceptive response was also examined. RESULTS: Oral administration of ARE did not affect the responses of the tail-flick, tail-pressure, or hot-plate test or the first phase of the formalin tests, but it dose-dependently decreased the duration of nociceptive behavior in the second phase, as did diclofenac, a non-steroidal anti-inflammatory drug. ARE also inhibited nociceptive behaviors induced by the intrathecal injection of NMDA, although diclofenac did not affect these behaviors. Pretreatment with bicuculline, a GABA(A) antagonist, reduced the antinociceptive effects of ARE on the formalin- or NMDA-induced behaviors. Muscimol, a GABA(A) agonist, exhibited antinociceptive effects in the formalin test and NMDA-induced behaviors in a manner similar to that of ARE. On the other hand, diclofenac significantly inhibited cyclooxygenase (COX)-1 and -2 activities, while ARE did not. CONCLUSION: These results suggest that ARE may inhibit development of hyperalgesia via NMDA receptors based on activation of GABA(A) receptors in the spinal cord.